Research Enhancement Programmes
Design and Measure EEG Change in Enhancement and Intervention Research
A Research Enhancement Programme is an optional study-design and analytical service for ethically approved research that evaluates whether a defined intervention, exposure or optimisation programme is associated with measurable EEG, qEEG or functional change over time.
Neuromap™ supports baseline mapping, hypothesis-led variable selection, repeat qEEG and objective pre/post comparison. It does not prescribe treatment and does not guarantee benefit.
How the Programme Works
- Baseline characterisation — technical quality, predefined variables and relevant context.
- Hypothesis and target mapping — prospectively defined domains, without converting associations into causal claims.
- Candidate research designs for investigator consideration — e.g. cognitive training, sleep, physical activity, behavioural, digital, rehabilitation, nutrition, pharmacological or neuromodulation research.
- Outcome and measurement plan — timing, repeat conditions, adherence, confound tracking and statistics.
- Repeat EEG and quality control — harmonised conditions and controlled settings.
- Objective change analysis — improvement, stability, divergence and potential regression.
- Research interpretation and publication support.
An Important Boundary
Neuromap™ does not prescribe treatment through this research service. Any intervention must be selected, approved and governed by the sponsor, principal investigator, ethics framework and appropriately qualified clinical or research professionals. Neuromap™ provides analytical guidance and hypothesis-led research options, not a guarantee of benefit.
Potential Research Uses
- Healthy-volunteer optimisation studies.
- Cognitive and vigilance programmes.
- Exercise and sleep research.
- Rehabilitation studies.
- Digital therapeutic evaluation.
- Pharmacodynamic research.
- Neurotechnology and neuromodulation studies.
- Education and behavioural research.
Measuring Change Responsibly
Because pre/post designs are vulnerable to regression to the mean, practice effects and session confounds, Neuromap™ emphasises harmonised repeat acquisition, prospective hypotheses and honest reporting of uncertainty, so that observed change is not over-interpreted as intervention effect.
What a Pre/Post qEEG Study Can and Cannot Show
A pre/post qEEG study can show whether EEG-derived measures changed between baseline and follow-up around a defined intervention or exposure. It cannot, on its own, prove that the intervention caused the change, because pre/post designs are vulnerable to regression to the mean, practice effects and natural variation. Neuromap™ frames pre/post qEEG analysis accordingly, as hypothesis-led research rather than proof of benefit.
- Can describe measured change between timepoints.
- Can compare change at participant, subgroup and cohort level.
- Cannot establish causation without appropriate controls.
- Cannot guarantee benefit from an intervention.
Strengthening a Pre/Post qEEG Design
The credibility of pre/post qEEG analysis improves with control conditions, prospective hypotheses, harmonised repeat acquisition and honest handling of confounds. Where ethically and practically possible, comparison or control groups substantially strengthen the inference available from a research enhancement programme.
Governance and Responsibility
In every research enhancement programme, the intervention is selected, approved and governed by the sponsor, principal investigator and ethics framework. Neuromap™ provides analytical guidance, baseline mapping, repeat qEEG and objective pre/post comparison – it does not prescribe treatment and does not guarantee benefit.
Examples of Pre/Post qEEG Research Designs
Pre/post qEEG research designs vary widely in strength. A single-arm baseline-to-follow-up study is the simplest but weakest; adding a control or comparison group substantially strengthens inference; randomisation, where ethical and feasible, strengthens it further. Neuromap™ can support pre/post qEEG analysis across this range and is candid about the inference each design supports.
- Single-arm baseline-to-follow-up (weakest inference).
- Comparison-group designs (stronger inference).
- Randomised designs where ethical and feasible (strongest).
- Crossover designs for within-participant comparison.
Keeping Research Enhancement Programmes Within Scope
A research enhancement programme stays within scope by remaining a research and analytics service. Neuromap™ provides baseline mapping, hypothesis-led variable selection, repeat qEEG and objective pre/post comparison. It does not select or prescribe interventions, does not provide clinical treatment and does not guarantee benefit – those responsibilities sit with the sponsor, principal investigator and qualified professionals under the approved protocol.
What You Receive
Programme engagements deliver baseline characterisation, repeat measurement and objective change analysis, with honest reporting of uncertainty.
- Structured, machine-readable data exports keyed by participant and visit.
- Clear tables and publication-oriented figures where requested.
- A documented record of settings, definitions and any exclusions.
- Study-level summaries at agreed milestones.
- Optional specialist scientific review at the contracted service level.
Every deliverable is prepared in professional British English and is designed to slot directly into the study team’s statistical, regulatory or manuscript workflow.
Getting Started
The intervention is always owned and governed by the study team.
The usual first step is a short feasibility review. The study team shares the research outline, the expected data volume, the acquisition details and the deliverables required. Compatibility is then confirmed and a study-specific scope and quotation provided before any commitment.
Strengthening the Inference Available
The simplest before-and-after comparison is also the weakest, because several ordinary phenomena can produce apparent change in the absence of any real effect. Regression to the mean, familiarity with the procedure and natural fluctuation can all mimic improvement. Recognising this from the outset shapes a more robust design and a more measured interpretation of whatever change is observed.
Inference improves markedly when a comparison or control group is added, and further still when allocation can be randomised, where that is ethical and feasible. Prospective hypotheses, harmonised repeat measurement and honest handling of confounds all contribute as well. Throughout, the intervention itself is chosen and governed by the study team under ethics approval; the analytical service measures possible change and reports it transparently, without prescribing treatment or promising benefit.
Key Terms Explained
The following terms appear across this area of research and may help teams new to advanced electrophysiology.
Pre/post design
Comparing measures before and after a defined period or intervention.
Control group
A comparison group that does not receive the intervention.
Regression to the mean
Movement of extreme initial values toward the average on retest.
Baseline mapping
Characterising the starting state before any intervention.
Principal investigator
The individual responsible for a study’s conduct and governance.
Ethics approval
Independent approval required before research involving participants proceeds.
A Note on Responsible Use
All outputs are provided for research use. They consist of data and neutral observations, and a suitably qualified clinician or investigator retains responsibility for interpretation, clinical meaning and any decisions that follow.
Summary
A research enhancement programme uses pre/post qEEG analysis to measure possible change around an ethically approved intervention. Neuromap™ supports the design and analysis honestly, without prescribing treatment or promising benefit.
Scope
Neuromap™ provides EEG and qEEG data analytics for research. Outputs are data and neutral observations only; a suitably qualified clinician or investigator completes all interpretation. Neuromap™ does not provide a clinical diagnosis and is not an accredited clinical diagnostic laboratory.
Frequently Asked Questions
Common questions about research enhancement programmes and pre/post qEEG analysis.
Does Neuromap™ recommend treatments?
Neuromap™ may provide research-design options and candidate modules for investigator consideration. Clinical treatment decisions sit outside this service and are governed by qualified professionals and the approved protocol.
Is benefit guaranteed?
No. This is a research service measuring possible change; it does not guarantee benefit.
What approvals are needed?
The study must be ethically approved, with the intervention controlled by the sponsor or principal investigator.
Who decides the intervention?
The sponsor or principal investigator, under ethics approval. The service provides research design options and analysis, not treatment selection.
Can you add a control group to strengthen the design?
Yes, where ethical and feasible; comparison or control groups substantially strengthen the inference available.
Limitations and Important Notes
- Pre/post designs are prone to regression to the mean and practice effects.
- Neuromap™ does not prescribe treatment or guarantee benefit.
- Any published figure for analytical-output count, reference datasets, processing capacity or turnaround is conditional on the documented platform version and the requirements of the specific study.